AzTrials
AzTrials

Spinal Muscular AtrophyPhase 3SHINENCT02594124

A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies

A Phase 3 study testing nusinersen in people with Spinal Muscular Atrophy, run by Biogen at 47 sites in 14 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The primary objective is to evaluate long-term safety and tolerability of nusinersen (ISIS 396443) administered by intrathecal (IT) injection to participants with Spinal Muscular Atrophy (SMA) who previously participated in investigational studies of nusinersen. Read more about this study

Who is it for?
Any age
Conditions the study is for
Spinal Muscular Atrophy
What is being tested?
nusinersen
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
292 participants
Where
47 sitesin 14 countries
Study dates
4 Nov 2015to 21 Aug 2023
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Signed informed consent of parent or guardian and signed informed assent of participant, if indicated per participant's age and institutional guidelines.
  • Completion of the index study in accordance with the study protocol or as a result of Sponsor decision (e.g., early termination of the index study) within the preceding 16 weeks

Who cannot join

  • Have any condition or worsening condition which in the opinion of the Investigator would make the participant unsuitable for enrollment, or could interfere with the participant participating in or completing the study
  • Clinically significant abnormalities in hematology or clinical chemistry parameters or electrocardiogram (ECG), as assessed by the Site Investigator, at the Screening visit that would render the participant unsuitable for participation in the study
  • Participant's parent or legal guardian is not willing or able to meet standard of care guidelines (including vaccinations and respiratory syncytial virus prophylaxis if available), nor provide nutritional and respiratory support throughout the study
  • Treatment with another investigational agent, biological agent, or device within one month of Screening, or 5 half-lives of study agent, whichever is longer
  • NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Trial locations and contacts

47 sites in 14 countries.

47 sites in 14 countries

United States18 sites
  • Children's Hospital Colorado

    Aurora, Colorado, 80045

  • The Johns Hopkins Hospital

    Baltimore, Maryland, 21287

  • Boston Children's Hospital

    Boston, Massachusetts, 02115

  • Children's Medical Center

    Dallas, Texas, 75235

  • Duke University School of Medicine

    Durham, North Carolina, 27710

  • Oregon Health Sciences University

    Durham, Oregon, 97239

  • Connecticut Children's Medical Center

    Hartford, Connecticut, 06106

  • David Geffen School of Medicine at UCLA

    Los Angeles, California, 90095-8344

  • Duke University School of Medicine

    Miyagi, North Carolina, 27710

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    New York, Illinois, 60611

  • Columbia University Medical Center

    New York, New York, 10032

  • University of Utah

    Obu, Aichi, Utah, 84112

  • Nemours Children's Clinic

    Orlando, Florida, 32827

  • Stanford University School of Medicine

    Palo Alto, California, 94305

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104

  • Gillette Children's Specialty Healthcare

    Saint Paul, Minnesota, 55101

  • Seattle Children's Hospital

    Seattle, Washington, 98105

  • Washington University School of Medicine

    St Louis, Missouri, 63110

Other trials in United States

Japan6 sites
  • Kumamoto University Hospital

    Kumamoto, 860-8556

  • Miyagi Prefectural Children Hospital

    Miyagi, 989-3126

  • University of Miyazaki Hospital

    Miyazaki, 889-1692

  • Hyogo College of Medicine

    Nishinomiya, Hyōgo, 663-8501

  • Aichi Children's Health and Medical Center

    Ōbu, Aichi-ken, 474-0038

  • Tokyo Women's Medical University

    Shinjuku-ku, Tokyo, 162-8666

Other trials in Japan

Canada3 sites
  • Children's Health Research Institute

    Brussel, Ontario, N6A 5W9

  • McGill University Health Centre

    Montreal, Quebec, H4A 3J1

  • BC Children's Hospital / UBC

    Vancouver, British Columbia, V6H 3V4

Other trials in Canada

Germany3 sites
  • Universitatsklinikum Essen

    Essen, 45147

  • Universitaetsklinikum Freiburg

    Freiburg im Breisgau, 79106

  • LMU-Campus Innenstadt

    Munich, Bavaria, 80337

Other trials in Germany

Italy3 sites
  • Pediatric Neurology Unit, Catholic University

    Essen, 00168

  • Istituto Giannina Gaslini, Centro Traslazionale di Miologia

    Genova, 16147

  • Department of Neuroscience, Università di Messina, AOU Polic

    Messina, 98125

Other trials in Italy

Spain3 sites
  • Hospital Sant Joan de Deu

    Barcelona, 08950

  • Hospital Universitario Vall de Hebron

    Hebron, 08035

  • Hospital Universitario La Paz

    Madrid, 28046

Other trials in Spain

Australia2 sites
  • Royal Children's Hospital

    Parkville, Victoria, 3052

  • Sydney Children's Hospital Clinical Research Centre

    Sydney, New South Wales, 2031

Other trials in Australia

Turkey (Türkiye)2 sites
  • Uníversity of Hacettepe

    Ankara, 6100

  • Marmara University Pendik Training and Research Hospital

    Istanbul, 34662

Other trials in Turkey (Türkiye)

United Kingdom2 sites
  • UCL Institute of Child Health

    London, WC1N 1EH

  • MRC Centre for Neuromuscular Diseases at Newcastle

    Newcastle, Northumberland, NE1 3BZ

Other trials in United Kingdom

Belgium1 site
  • Universitair Kinderziekenhuis Koningin Fabiola

    Brussels, 1020

Other trials in Belgium

France1 site
  • Armand Trousseau Hospital, I-Motion

    Paris, Paris 9, 75012

Other trials in France

Hong Kong1 site
  • The University of Hong Kong

    Hong Kong, Hong Kong SAR, 999077

Other trials in Hong Kong

South Korea1 site
  • Seoul National University Hospital

    Seoul, Korea, 3080

Other trials in South Korea

Sweden1 site
  • The Queen Silvia Children's Hospital

    Gothenburg, SE 416 86

Other trials in Sweden

About this study

Official title: An Open-Label Extension Study for Patients With Spinal Muscular Atrophy Who Previously Participated in Investigational Studies of ISIS 396443

The primary objective is to evaluate long-term safety and tolerability of nusinersen (ISIS 396443) administered by intrathecal (IT) injection to participants with Spinal Muscular Atrophy (SMA) who previously participated in investigational studies of nusinersen. The secondary objective is to examine the long-term efficacy of nusinersen administered by IT injection to participants with SMA who previously participated in investigational studies of nusinersen.

Read the detailed description

This study was initiated and the protocol was registered by Ionis Pharmaceuticals, Inc.

In August 2016, Biogen assumed responsibility for this study.

Being tested
nusinersen
Keywords
SMA, SMN, SMNRx, ISIS-SMNRx, ISIS 396443, SHINE, IONIS-SMNRx, IONIS-SMN Rx, Spinraza, nusinersen
Medical subject headings
Muscular Atrophy, Spinal

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • nusinersenDrug

    Also called ISIS 396443, Spinraza, BIIB058, IONIS SMN Rx

    Administered by intrathecal (IT) injection

Study groups in NCT02594124
Study groupRoleWhat they receive
Group 1ExperimentalParticipants transitioned from ISIS 396443-CS3B (NCT02193074)
Receives: Drug: nusinersen
Group 2ExperimentalParticipants transitioned from ISIS 396443-CS4 (NCT02292537)
Receives: Drug: nusinersen
Group 3ExperimentalParticipants transitioned from ISIS 396443-CS12 (NCT02052791)
Receives: Drug: nusinersen
Group 4ExperimentalParticipants transitioned from ISIS 396443-CS3A (NCT01839656)
Receives: Drug: nusinersen
Group 5ExperimentalParticipants transitioned from 232SM202 (NCT02462759)
Receives: Drug: nusinersen

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    AE:unfavorable and unintended sign, symptom, or disease temporally associated with study/use of an investigational drug, whether or not it's considered related to investigational drug. SAE:AE that in view of either Investigator/Sponsor, meets any of the following criteria: results in death;is life-threatening:i.e.poses risk of death, hospitalization/it's prolongation;results in a persistent or significant incapacity or substantial disruption of normal life functions;results in congenital anomaly or birth defect in offspring;is an important event in the opinion of Investigator/Sponsor. TEAE: if it was present prior to first dose of nusinersen or first sham procedure in index study and subsequently worsened in severity/was not present prior to first dose of nusinersen or first sham procedure in index study but subsequently appeared.

    Measured: From Day 1 up to the end of the study (up to 2848 days)

  2. Number of Participants With Vital Sign Abnormalities Reported as AEs

    The vital sign assessments included blood pressure, temperature, pulse rate, and respiratory rate. Participants with abnormalities in these assessments recorded as AEs were reported.

    Measured: From Day 1 up to the end of the study (up to 2848 days)

  3. Number of Participants With Weight Abnormalities Reported as AEs

    Weight decrease was characterized by a decrease of >=7% from baseline and weight increase was characterized by an increase of >=7% from baseline. Participants with these abnormalities recorded as AEs were reported.

    Measured: From Day 1 up to the end of the study (up to 2848 days)

  4. Number of Participants With Neurological Abnormalities Reported as AEs

    Participants with abnormalities in neurological examinations recorded as AEs were reported.

    Measured: From Day 1 up to the end of the study (up to 2848 days)

  5. Number of Participants With Laboratory Abnormalities Reported as AEs

    Laboratory investigations included hematology, coagulation, serum chemistry and urinalysis parameters. Participants with abnormalities in these laboratory investigations recorded as AEs were reported.

    Measured: From Day 1 up to the end of the study (up to 2848 days)

  6. Number of Participants With Coagulation Parameters Reported as AEs

    Coagulation parameters included activated partial thromboplastin time (aPTT) and international normalized ratio (INR). Participants with abnormalities in these coagulation parameters recorded as AEs were reported.

    Measured: From Day 1 up to the end of the study (up to 2848 days)

  7. Number of Participants With Clinically Significant Shifts in12 Lead Electrocardiogram (ECG) Results

    Clinical significance of abnormalities in 12 lead ECG was determined based on the investigator's discretion.

    Measured: From Day 1 up to the end of the study (up to 2848 days)

  8. Number of Participants Taking Any Concomitant Medication

    A concomitant therapy is any non-protocol-specified drug or substance (including over-the-counter medications, herbal medications, and vitamin supplements) administered between the beginning of screening and the last telephone contact or study visit.

    Measured: From Day 1 up to the end of the study (up to 2848 days)

Secondary outcomes (24)
  1. Mean Number of New Motor Milestones Achieved as Assessed by World Health Organization (WHO) Criteria

    The WHO motor milestones are a set of six milestones in motor development, all of which would be expected to be attained by 24 months of age in healthy children. The individual milestones are: sitting without support, standing with assistance, hands and knees crawling, walking with assistance, standing alone and walking alone. Mean of number of new milestones achieved was calculated and reported in this outcome measure.

    Measured: MMDR Period: At Day 1800

  2. Percentage of Participants With <2 Years of Age Who Attained Motor Milestones as Assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)

    HINE is evaluated in infants between 2-24 months of age. It's a simple, standardized instrument including 26 items assessing different aspects of neurological examinations, such as cranial nerves, posture, movements, tone, and reflexes. In this study, Module 2 of HINE (HINE-2) was assessed, which evaluates 8 developmental milestones (head control, sitting, voluntary grasp, ability to kick, rolling, crawling, standing, and walking) scored on a 3, 4, or 5-point scale, with 0 indicating inability to perform task and score of 2, 3, or 4 indicating full milestone development. Total score is calculated by summing item scores to give maximum possible score of 26. Higher score indicates good neurological function.

    Measured: At Day 309

  3. Number of Participants Who Died or Met Permanent Ventilation

    Permanent ventilation was defined as tracheostomy or >=16 hours of ventilator support per day continuously for >21 days in the absence of an acute reversible event.

    Measured: MMDR Period: Up to Day 1800

  4. Number of Participants Not Requiring Permanent Ventilation

    Permanent ventilation was defined as tracheostomy or >=16 hours of ventilator support per day continuously for >21 days in the absence of an acute reversible event.

    Measured: MMDR Period: Up to Day 1800

  5. Change From Baseline in Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) Motor Function Scale

    The CHOP INTEND test is designed to evaluate the motor skills of infants with significant motor weakness, including infants with SMA. Participants who are ≥2 years will be continued to be assessed until a CHOP INTEND maximum score of 64 is achieved. It includes 16 items structured to move from easiest to hardest with the grading including gravity eliminated (lower scores) to antigravity movements (higher scores). All item scores range from 0 (worst) to 4 (best). Total scores range from 0 to 64, with higher scores indicating better movement functioning.

    Measured: Baseline, Day 2198

  6. Change From Baseline in Hammersmith Functional Motor Scale Expanded (HFMSE) Total Score

    The HFMSE consists of 33 scored activities used to assess motor function in children with SMA. Participants were asked to do a specific activity (such as rolling) and they were then graded on the quality and execution of that movement on a scale of 0=being unable, 1=performed with some compensation, and 2=unaided. The overall score is the sum of the scores for all activities with a maximum achievable score of 66. Higher scores indicate increased motor function.

    Measured: MMDR Period: Baseline, MMDR Day 1800

  7. Change From Baseline in Revised Upper Limb Module (RULM) Total Score

    RULM Test is used in participants with SMA to assess upper limb functional ability items and has total of 20 items with an entry item that serves as functional class identification and does not contribute to total score. Remaining 19 scorable items reflect different functional domains and graded on 3-point system with score of 0 (unable), 1 (able, with modification), and 2 (able, no difficulty). There is only 1 item that is scored as a can/cannot score, with 1 as the highest score. Scorable items are summed for total score (0-37), higher scores indicating increased upper limb function. Positive change from baseline indicates improvement.

    Measured: MMDR Period: Baseline, MMDR Day 1800

  8. Change From Baseline in Total Distance Walked Over Time as Assessed by 6-Minute Walk Test (6MWT)

    The 6MWT measures the distance an individual can walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes.

    Measured: Baseline, Day 2670

  9. Number of Participants Who Experienced Contracture Assesment

    Contracture assessment is performed to assess the motor performance in SMA. The number of participants who experienced at least one contracture at any location and severe contractures in any of the five locations (hip flexors, knee flexors, ankle planter flexors, elbow flexors, forearm flexors) are reported in this outcome measure.

    Measured: MMDR Period: At MMDR Day 1800

  10. Change From Baseline in Compound Muscular Action Potential (CMAP)

    CMAP is an electrophysiological technique that can be used to determine the approximate number of motor neurons in a muscle or group of muscles. Peroneal amplitude (PA) and ulnar amplitude (UA) data is reported in this OM. Score <0 indicated worse response and >0 indicated better response than the normal matched population. Score change <0 indicated worsening and >0 indicated improvement as compared to baseline.

    Measured: MMDR Period: Baseline, MMDR Day 1800

  11. Change From Baseline in Body Length

    Participants were analyzed for change in growth parameter of body length to evaluate clinical efficacy. The body length was calculated using either WHO or Centers for Disease Control and Prevention (CDC) scales. The CDC scale allows to calculate the body length up to 20 years, while the WHO scale allows to calculate it only up to 10 years.

    Measured: MMDR Period: up to Day 1800

  12. Change From Baseline in Weight

    Participants were analyzed for change in growth parameter of weight to evaluate clinical efficacy. The weight was calculated using either WHO or CDC scales. The CDC scale allows to calculate the weight up to 20 years, while the WHO scale allows to calculate it only up to 10 years.

    Measured: MMDR Period: up to Day 1800

  13. Change From Baseline in Weight for Age Percentile

    Participants who were below the age of 36 months were analyzed for change in growth parameter of weight for age to evaluate clinical efficacy. The weight for age percentile was calculated using either WHO or CDC scales. The CDC scale allows to calculate the weight for age percentile up to 20 years, while the WHO scale allows to calculate it only up to 10 years.

    Measured: MMDR Period: up to Day 1800

  14. Percentage of CMAP Responders

    CMAP is an electrophysiological technique that can be used to determine the approximate number of motor neurons in a muscle or group of muscles. A participant was defined as a responder if they had a peroneal amplitude ≥1 mV at last visit (including the amplitude ≥1 mV at baseline and also demonstrated as such at last visit).

    Measured: MMDR Period: At Day 1800

  15. Number of Participants Who Achieved Motor Milestones

    Motor milestones were measured based on WHO criteria. The WHO motor milestones are a set of six milestones in motor development, all of which would be expected to be attained by 24 months of age in healthy children. The individual milestones are: sitting without support (SWS), standing with assistance (SWA), hands and knees crawling (HKC), and walking alone (WA).

    Measured: MMDR Period: up to Day 1800

  16. Number of Participants Who Achieved Standing Alone and Walking With Assistance

    Motor milestones were measured based on WHO criteria. The WHO motor milestones are a set of six milestones in motor development, all of which would be expected to be attained by 24 months of age in healthy children. The individual milestones are: SWS, SWA, HKC, WWA, WA and standing alone (SA). SA and WWA were assessed in this outcome measure.

    Measured: MMDR Period: up to Day 1800

  17. Total Number of Hospitalizations Due to Serious Respiratory Events

    Total number of hospitalizations is total number of serious events that occurred during study for all participants under each group. For a participant with multiple SAEs which started at the same date and led to hospitalization, it is counted as one hospitalization.

    Measured: Up to day 2520

  18. Total Number of Hospitalizations Due to Serious Adverse Events

    Total number of hospitalizations is total number of serious events that occurred during study for all participants under each group. For a participant with multiple SAEs which started at the same date and led to hospitalization, it is counted as one hospitalization.

    Measured: Up to day 2520

  19. Percent of Time in Hospitalization

    Measured: Upto day 2160

  20. Change From Baseline in Cobb-Angle on X-Ray of the Thoracolumbar Spine by Visit

    Cobb angle is a measurement of the degree of side-to-side spinal curvature used to define scoliosis.

    Measured: MMDR Period: Baseline, MMDR Day 1800

  21. Pediatric Quality of Life Inventory (PedsQL) Questionnaires Total Score by Domain

    Items on the PedsQL generic core scale are reverse scored and transformed to a 0-100 scale. The PedsQL parent (P) and self (S) reported questionnaire was collected for participants from 2 to 25 years of age. Four dimensions were collected: Physical, Emotional, Social and School functioning and each item was scored on a 5 point ordinal scale. 0 (never) =100, 1 (almost never) = 75, 2 (sometimes)= 50, 3 (often) = 25, 4 (almost always) = 0. A total score was calculated as the sum of all the items over the number of items answered on all the scales. If more than 50% of items or more were missing, the scale score was not computed. Higher scores indicated better health related quality of life.

    Measured: MMDR Period: At Day 1800

  22. Change From Baseline in Assessment of Caregiver Experience With Neuromuscular Disease (ACEND) Questionnaire Total Score

    The ACEND is a questionnaire that includes a total of seven domains assessing physical impact (including feeding/grooming/dressing, sitting/play, transfers, and mobility) and general caregiver impact (including time, emotion, and finance) and each domain comprises several items. The total score (TS) for each domain will be calculated on a scale of 0 to 100. Higher scores indicate a greater impact on the caregiver.

    Measured: MMDR Period: up to Day 1800

  23. Number of Participants With Disease-related Hospitalizations and AEs

    Measured: MMDR Period: up to Day 1800

  24. Survival Rate

    Survival rate was defined as the percentage of participants alive during the study and was estimated from the Kaplan Meier (KM) curve for time to death.

    Measured: MMDR Period: up to Day 1800

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Nov 2015 (estimated)
  2. Study start4 Nov 2015
  3. Primary completion21 Aug 2023
  4. Study completion21 Aug 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
292 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02594124
Sponsor's protocol ID
ISIS 396443-CS11
Other IDs
2015-001870-16, 2015
Acronym
SHINE
Status last verified
Sep 2024
First submitted
30 Oct 2015
Last updated
22 Oct 2024
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Expanded access
Available

Publications

  • Kokaliaris C, Evans R, Hawkins N, Mahajan A, Scott DA, Sutherland CS, Nam J, Sajeev G. Long-Term Comparative Efficacy and Safety of Risdiplam and Nusinersen in Children with Type 1 Spinal Muscular Atrophy. Adv Ther. 2024 Jun;41(6):2414-2434. doi: 10.1007/s12325-024-02845-6. Epub 2024 May 5.

    PubMed 38705943

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing nusinersen in people with Spinal Muscular Atrophy, run by Biogen at 47 sites in 14 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 47 sites in United States, Japan, Canada, Germany, Italy and 9 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 22 Oct 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) (time frame: From Day 1 up to the end of the study (up to 2848 days)). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02594124, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Oct 2024.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in